Nystagmus Market Share And Application By Type (Infantile, Latent Nystagmus, Noonan Syndrome, Nystagmus Blockage Syndrome) Diagnosis (Ct Scan, Mr Scan, Chromosome Analysis, Ultrasonography) Treatment (Medication, Surgical) End-User-Forecast Till 2027
ID: MRFR/Pharma/3995-HCR | August 2022 | Region: Global | 110 Pages
Table of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Nystagmus Market, by Type
6.1 Introduction
6.2 Infantile
6.2.1 Market Estimates & Forecast, 2020-2027
6.3 Latent Nystagmus
6.3.1 Market Estimates & Forecast, 2020-2027
6.4 Noonan Syndrome
6.4.1 Market Estimates & Forecast, 2020-2027
6.5 Nystagmus Blockage Syndrome
6.5.1 Market Estimates & Forecast, 2020-2027
7. Global Nystagmus Market, by Diagnosis
7.1 Introduction
7.2 CT scan
7.2.1 Market Estimates & Forecast, 2020-2027
7.3 MR scan
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Others
7.4.1 Market Estimates & Forecast, 2020-2027
8. Global Nystagmus Market, by Treatment
8.1 Introduction
8.2 Medication
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Surgery
8.3.1 Market Estimates & Forecast, 2020-2027
9. Global Nystagmus Market, by End User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2020-2027
9.3 Research Centers
9.3.1 Market Estimates & Forecast, 2020-2027
9.4 Others
9.4.1 Market Estimates & Forecast, 2020-2027
10. Global Nystagmus Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Bristol-Myers Squibb Company
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 NUSAPURE
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 ALLERGAN
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Aerie Pharmaceuticals, Inc.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Pfizer Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Valeant Pharmaceuticals International, Inc
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Bayer AG
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical Industry
14 Appendix
LIST OF TABLES
Table 1 Nystagmus Industry Synopsis, 2020-2027
Table 2 Global Nystagmus Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Global Nystagmus Market by Region, 2020-2027, (USD Million)
Table 4 Global Nystagmus Market by Types, 2020-2027, (USD Million)
Table 5 Global Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 6 Global Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 7 Global Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 8 North America Nystagmus Market by Types, 2020-2027, (USD Million)
Table 9 North America Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 10 North America Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 11 North America Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 12 US Nystagmus Market by Types, 2020-2027, (USD Million)
Table 13 US Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 14 US Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 15 US Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 16 Canada Nystagmus Market by Types, 2020-2027, (USD Million)
Table 17 Canada Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 18 Canada Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 19 Canada Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 20 South America Nystagmus Market by Types, 2020-2027, (USD Million)
Table 21 South America Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 22 South America Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 23 South America Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 24 Europe Nystagmus Market by Types, 2020-2027, (USD Million)
Table 25 Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 26 Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 27 Europe Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 28 Western Europe Nystagmus Market by Types, 2020-2027, (USD Million)
Table 29 Western Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 30 Western Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 31 Western Europe Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 32 Eastern Europe Nystagmus Market by Types, 2020-2027, (USD Million)
Table 33 Eastern Europe Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 34 Eastern Europe Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 35 Eastern Europe Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 36 Asia Pacific Nystagmus Market by Types, 2020-2027, (USD Million)
Table 37 Asia Pacific Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 38 Asia Pacific Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 39 Asia Pacific Nystagmus Market by End Users, 2020-2027, (USD Million)
Table 40 Middle East & Africa Nystagmus Market by Types, 2020-2027, (USD Million)
Table 41 Middle East & Africa Nystagmus Market by Diagnosis, 2020-2027, (USD Million)
Table 42 Middle East & Africa Nystagmus Market by Treatment, 2020-2027, (USD Million)
Table 43 Middle East & Africa Nystagmus Market by End Users, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Nystagmus Market
Figure 3 Segmentation Market Dynamics for Nystagmus Market
Figure 4 Global Nystagmus Market Share, by Diagnosis 2020
Figure 5 Global Nystagmus Market Share, by Treatment 2020
Figure 6 Global Nystagmus Market Share, by End Users, 2020
Figure 7 Global Nystagmus Market Share, by Region, 2020
Figure 8 North America Nystagmus Market Share, by Country, 2020
Figure 9 Europe Nystagmus Market Share, by Country, 2020
Figure 10 Asia Pacific Nystagmus Market Share, by Country, 2020
Figure 11 Middle East & Africa Nystagmus Market Share, by Country, 2020
Figure 12 Global Nystagmus Market: Company Share Analysis, 2020 (%)
Figure 13 Bristol-Myers Squibb Company: Key Financials
Figure 14 Bristol-Myers Squibb Company: Segmental Revenue
Figure 16 Bristol-Myers Squibb Company: Geographical Revenue
Figure 17 NUSAPURE: Key Financials
Figure 18 NUSAPURE: Segmental Revenue
Figure 19 NUSAPURE: Geographical Revenue
Figure 20 ALLERGAN: Key Financials
Figure 21 ALLERGAN: Segmental Revenue
Figure 22 ALLERGAN: Geographical Revenue
Figure 23 Aerie Pharmaceuticals, Inc: Key Financials
Figure 24 Aerie Pharmaceuticals, Inc: Segmental Revenue
Figure 25 Aerie Pharmaceuticals, Inc: Geographical Revenue
Figure 26 Pfizer Inc: Key Financials
Figure 27 Pfizer Inc: Segmental Revenue
Figure 28 Pfizer Inc: Geographical Revenue
Figure 29 Valeant Pharmaceuticals International, Inc.: Key Financials
Figure 30 Valeant Pharmaceuticals International, Inc.: Segmental Revenue
Figure 31 Valeant Pharmaceuticals International, Inc.: Geographical Revenue
Figure 32 Bayer AG: Key Financials
Figure 33 Bayer AG: Segmental Revenue
Figure 34 Bayer AG: Geographical Revenue
Nystagmus Market
Nystagmus Market is projected to be worth USD 3.8 Billion by 2028, registering a CAGR of 7.2% during the forecast period (2021 - 2028).
$3.8 Billion
Market Size
7.2%
CAGR
North America
Dominating Region
2021-2028
Forecast Period
Segmentation
Key Players
- Bristol-Myers Squibb Company
- NUSAPURE
- ALLERGAN
- Aerie Pharmaceuticals Inc.
- Pfizer Inc.
- Valeant Pharmaceuticals International.
- Bayer AG
- Genentech Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Shire
- Santen Pharmaceutical Co. Ltd.
Drivers
- Increasing prevalence of the genetic and eye related disorders
- Increasing mental retardation and neurological abnormalities
Nystagmus Market Overview
The global nystagmus market is expected to grow at a CAGR of approximately 6.2% during the forecast period, 2017-2023. Nystagmus is a vision-related medical disease characterized by uncontrolled and repeated eye movements. These motions frequently result in blurred vision, which may wreak havoc on the body's balance and coordination. The prognosis of nystagmus is worsened by fatigue and stress. The specific source of the disease, however, is yet unknown. Congenital neurological problems or neurological abnormalities developing in childhood are the most common causes of nystagmus.
Nystagmus can also be caused by a lack of normal eye movement in childhood, refractive errors such as near-sightedness (myopia) or astigmatism, inflammation of the inner ear, medicines such as anti-epilepsy treatments, and central nervous system illnesses. The rising frequency of genetic and eye-related illnesses is driving the expansion of the nystagmus industry. Furthermore, the market will grow as mental retardation and neurological disorders become more prevalent.
Global Nystagmus Market, by region 2016(%)
Segmentation:
The nystagmus market is segmented on the basis of type, diagnosis, treatment, and end-users.
Based on the type, the market is segmented into infantile, latent nystagmus, noonan syndrome, and nystagmus blockage syndrome.
On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.
On the basis of the treatment, the market is segmented into medications, surgical, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.
Regional Analysis:
The global nystagmus market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominate the global nystagmus market owing to well-developed technology, increasing number of patients with eye-related problems, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies in the region have fuelled the growth of the market in this region.
Europe holds the second position in the global nystagmus market owing to the government support for research & development and availability of funds for research. Moreover, this is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing their investments in the healthcare domain.
Asia Pacific is the fastest growing nystagmus market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for eye diseases in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, growing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, will increase the market growth of nystagmus in the region.
On the other hand, in the Middle East and Africa, eye problems have become a huge issue due to limited screening, ignorance of diseases, and poor access to treatment.
Key Players:
Some of key the players in the global nystagmus market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.
Recent Development
Regeneron Pharmaceuticals, Inc. is a biotechnology business that specializes in drug research, development, manufacturing, and commercialization. EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP are among the company's product lines. The company's own VelociSuite technologies, such as VelocImmune, which employs genetically humanized mice to manufacture optimized totally human and bispecific antibodies, help to speed up the traditional drug development process.
Bristol-Myers Squibb is a biopharmaceutical corporation. Biopharmaceutical products are discovered, developed, licensed, manufactured, marketed, distributed, and sold by the company. Oncology, immunology, cardiovascular disease, and fibrosis are among the therapeutic classes for which the company produces pharmaceuticals. Chemically manufactured or tiny molecule medications, as well as biologics created through biological processes, are among the company's pharmaceutical goods. Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude, and Breyanzi are some of the company's products. Wholesalers, distributors, pharmacies, merchants, hospitals, clinics, and government organizations are all customers of its goods.
Intended Audience:
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Research Methodology:
Sources: Annual reports, Press release, White paper, and Company presentation
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | Significant Value |
| CAGR | 2017-2023:6.1% |
| Base Year | 2019 |
| Forecast Period | 2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, diagnosis, treatment, and end-users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others |
| Key Market Opportunities |
|
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Nystagmus market is expected to exhibit a CAGR of 6.2% from 2017 to 2023.
Nystagmus market is driven by the high prevalence of genetic and eye disorders.
Lack of effective reimbursement schemes and offering of expensive treatment can hamper the global nystagmus market growth.
The Americas can be dominant in the global nystagmus market till 2023.
Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bayer AG, NUSAPURE, ALLERGAN, Novartis AG, Genentech, Inc., Aerie Pharmaceuticals, Inc., Pfizer Inc., Shire, Bristol-Myers Squibb Company, and Valeant Pharmaceuticals International, Inc. are key players of the global nystagmus market.
